NYSE · Medical - Diagnostics & Research

Invitae Corporation (NVTA) Stock

$0.02 -35.59% NYSE: NVTA Healthcare

Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services.

Valuation

MetricValue
Price$0.02
Market Cap$5.44M
P/E Ratio0.00
P/B Ratio0.04
P/S Ratio0.01
EPS (TTM)$-13.18
52-Week High$2.34
52-Week Low$0.02
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-201.69%
ROA-158.96%
ROCE-38.69%
Gross Margin19.18%
Operating Margin-138.34%
Net Margin-601.64%
Debt/Equity17.19
Current Ratio6.41

Annual Financials (USD)

Metric20182019202020212022
Revenue$148.0M$217.0M$280.0M$460.0M$516.0M
Operating Profit$-123.0M$-244.0M$-652.0M$-778.0M$-714.0M
Net Profit$-129.0M$-242.0M$-609.0M$-379.0M$-3.1B
EPS$-1.94$-2.66$-4.52$-1.80$-13.18
Op Margin-83.0%-112.6%-233.3%-169.0%-138.3%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$283.0M$782.0M$3.4B$4.9B$2.0B
Total Liabilities$121.0M$402.0M$1.5B$1.9B$1.9B
Cash$112.0M$151.0M$125.0M$923.0M$257.0M
Borrowings$78.0M$319.0M$450.0M$1.7B$1.8B

Latest News

Nvidia just locked down deal that changes AI race TheStreet · Jul 26, 2026 Dow Jones Futures Due, Iran News In focus; Apple Leads Earnings Wave, Fed Meeting Ahead Investor's Business Daily · Jul 26, 2026 Brown-Forman Board Issues Statement Business Wire · Jul 26, 2026 Brazil recalls ambassador to Argentina over Milei's Bolsonaro rally speech AFP · Jul 26, 2026 Baker Hughes Announces Second-Quarter 2026 Results GlobeNewswire · Jul 26, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-92.0M$-145.0M$-299.0M$-560.0M$-493.0M
Investing Cash Flow$30.0M$-300.0M$-423.0M$-259.0M$-228.0M
Financing Cash Flow$157.0M$465.0M$673.0M$1.6B$2.0M
Net Cash Flow$101.0M$39.0M$-26.0M$802.0M$-666.0M
Free Cash Flow$-98.0M$-165.0M$-322.0M$-615.0M$-546.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.52
FCF Yield-10035.52%
Quick Ratio6.13
Interest Coverage-12.59
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Invitae Corporation

Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.

Invitae Corporation is headquartered in US.

Invitae Corporation (NVTA) stock trades at $0.02 with a market capitalization of $5.44M. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.04, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.02 and $2.34, and currently trades 99.1% below its 52-week high.

On profitability, Invitae Corporation generates a return on equity (ROE) of -201.69%, return on capital employed of -38.69%, an operating margin of -138.34%, a net profit margin of -601.64%.

Official website: www.invitae.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides